EFCG to Hold its Annual Dinner on 14 October 2015 at The Prado Museum Madrid During CPHI
The Board of the European Fine Chemicals Group (EFCG) announces that the 8th EFCG Annual Dinner will be held on 14 October, 2015 at the famous Prado Museum, Madrid during CPHI Worldwide.
Mr Guy Villax, CEO of Hovione FarmaCiencia SA and Chairman of the Organising Committee said:“This year’s dinner will be less formal, more enjoyable and will promote networking. It will take place at the Prado Museum, include a guided tour in your preferred language and close with a tapas-style dinner. Our Annual dinner brings together the top management from the European Fine Chemicals Industry with their counterparts in the worldwide pharma innovator and generic industries”.
The evening will begin at 8.30pm with a private guided tour of the Prado followed by drinks and dinner - tapas style ending at 11.30pm.
EFCG was formed in 2004 to be the focus, the forum and the voice of European Fine Chemical Manufacturers. EFCG is a non-profit international sector group within Cefic — the Brussels-based European Chemical Industry Council — which respresents 29,000 companies producing 17% of the world’s chemicals and employing 1.2 million people and contributing €527 billion to the EU economy.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance